The Developmentally Regulated Avian Ch21 Lipocalin Is an Extracellular Fatty Acid-binding Protein*

Fiorella DescaIzi Cancetta§, Mara Malpelì, Chiara Gentili, Vincenzo Di Marzo, Paola Bet, Mariella Carlevaro, Silvia Cermelli, and Ranieri Cancetta

From the ‡Centro di Biotecnologie Avanzate, Istituto Nazionale per la Ricerca sul Cancro and ‡Istituto di Oncologia Clinica e Sperimentale, Università di Genova, 16132 Genova, Italy, and the †Istituto Internazionale di Genetica e Biofisica and ‡Istituto per la Chimica di Molecole di Interesse Biologico, Consiglio Nazionale delle Ricerche, 80100 Napoli, Italy

Ch21, a developmentally regulated extracellular protein expressed in chick embryos and in cultured chondrocytes, was expressed in the baculovirus system, and the recombinant protein was purified to homogeneity by gel-filtration chromatography. Separation of two isoforms was achieved on an ion-exchange column. Previous work had shown that Ch21 belongs to the superfAMILY OF LIPOCALINS, which are transport proteins for small hydrophobic molecules. Studies were performed to identify the Ch21 ligand.

By analysis of recombinant Ch21 on native polyacrylamide gel electrophoresis and by Lipidex assay, the binding of fatty acid to the protein was shown and a preferential binding of long-chain unsaturated fatty acids was observed. Both isoforms had the same behavior. The binding was saturable. Stoichiometry was about 0.7 mol of ligand/mol of protein. The protein binds the ligand in its monomeric form. Calculated dissociation constants were $2 \times 10^{-7}$ M for unsaturated fatty acids and $5 \times 10^{-3}$ M for stearic acid. The binding was specific; other hydrophobic molecules, as retinoic acid, progesterone, prostaglandins, and long-chain alcohols and aldehydes did not bind to the protein. Short-chain fatty acids did not bind to the protein.

Ch21, also present in chicken serum, represents the first extracellular protein able to selectively bind and transport fatty acid in extracellular fluids and serum. We propose to rename the Ch21 protein as extracellular fatty acid-binding protein (Ex-FABP).

In the last several years, our laboratory has focused on the cellular and molecular mechanisms that control endochondral bone formation. The process is characterized by the differentiation of prechondrogenic mesenchymal cells to resting, proliferating, and hypertrophic chondrocytes (1–8) and then by the replacement of hypertrophic cartilage by bone, i.e. cartilage calcification, erosion, invasion by blood vessels, and onset of osteogenesis. Hypertrophic chondrocytes play a critical role in the last part of the process. In fact they can undergo further differentiation to osteoblast-like cells both in vitro (9) and, in selected bone regions, in vivo (10–14) and are essential to the deposition of the first bone on newly synthesized bone sialoprotein-rich matrix (‘bone priming’). Recent data suggest that the initial bone deposition may be activated through the expression of the Krox-20 gene by hypertrophic chondrocytes (15). In addition, hypertrophic chondrocytes express and secrete, into the extracellular matrix, diffusable factors promoting angiogenesis (16). During the whole process, it is possible to observe the progressive synthesis of several proteins whose temporal and spatial appearance marks each cell differentiation stage. Hypertrophic chondrocytes secrete relatively large amounts of transferin both in vitro and in vivo (17, 18). The receptors for this factor are highly expressed in surrounding osteoblasts and preosteoblasts, suggesting a paracrine stimulation of these cells.

Hypertrophic chondrocytes synthesize and secrete large amounts of Ch21 protein, a low molecular weight protein belonging to the lipocalin superfamily (19–22). Members of this family have a molecular weight of about 20,000, a 20–30% homology, and share a basic framework for binding and transport of small hydrophobic molecules (23). The specific ligands for some of these proteins have been identified. They represent a wide variety of hydrophobic molecules: retinol (retinol-binding protein, Ref. 24); purpurin, Ref. 25; β-lactoglobulin, Ref. 23; retinoic acid (epididymal retinoic acid-binding protein, Ref. 26); biliverdin (insecticyanin, Refs. 27 and 28); odorants (odorant-binding protein, Ref. 29); progesterone (apolipoprotein D, Ref. 30); pheromone (urinary proteins, Ref. 31). In the present study, we have investigated the nature of the ligand for the Ch21 protein and its possible function. We present evidence that the recombinant Ch21 expressed in baculovirus-infected cells selectively binds long chain fatty acids. Unsaturated fatty acids, like oleic, linoleic, and arachidonic acid, are preferentially bound. The unsaturated fatty acids bind to the monomeric form of the protein with a $K_d$ in the order of $10^{-7}$ M. The presence of the Ch21 protein in the bone growth plate and its synthesis by hypertrophic chondrocytes and osteoblasts raise the question of the importance of lipid and fatty acid metabolism in cartilage development and bone formation.

Interestingly Ch21 is also detectable in serum, in agreement with the idea that its role may be more general. Intracellular fatty acid-binding proteins have been purified from a variety of tissues, including intestine, liver, heart, mammary, Schwann cell, and adipose (32–37). These intracellular-binding proteins have a molecular weight of about 14,000. Extracellular fatty acids are transported by albumin in blood stream (38). To our knowledge, the Ch21 represents the first...
example of an extracellular protein able to selectively bind and transport fatty acids in extracellular fluids and blood.

**EXPERIMENTAL PROCEDURES**

**Materials**

[1-3H]Linoleic acid, [1-14C]Meic acid, [1-3H]arachidonic acid, [1-3H]sclerotic acid (50–60 mCi/mmol) were from Amersham International Srl., Buckinghamshire, United Kingdom; [1-3H]linoleic acid (1 Ci/mmol) and [1-3H]arachidonic acid (50–60 mCi/mmol) were purchased from NEN Du Pont De Nemours, Dreieich, Germany. Nonradioactive fatty acids, oleyl alcohol, cis-13-octadecenal, hydroxylalkoxypropyl dextran type III, prostaglandin E2, and prostaglandin D2 were purchased from Sigma.

Centricon 10 and Centriprep 10 were purchased from Amicon, Beverly, MA. Polyacrylamide gel electrophoresis reagents were purchased from Bio-Rad. Ethyl acetate was HPLC grade from BDH, Poole, United Kingdom. Mono Q and Superdex 75 columns were purchased from Pharmacia Biotech, Uppsala, Sweden. ACA 54 resin was purchased from IBF Biotecnics, Villeneuve la Garenne, France. SF900 medium was from purchased Life Technologies, Inc., S. Giuliano Milanese, Italy.

**Expression of Recombinant Ch21 in Baculovirus-infected Cells**

Ch21 protein was produced in the baculovirus system according to published procedure (39). The PST1-ECORI pDr5 fragment (766 base pairs) of the pDr5 DNA coding for the Ch21 (22) was inserted in the BamH I site of pAcYM1. Recombinant baculoviruses were obtained by cotransfection of Sf9 cells with wild type AcMNPV and pACymI/pDr5 and purified by limiting dilution and dot hybridization.

For production of Ch21 protein, SF9 cells were grown in SF900 medium without fetal calf serum and infected with purified recombinant virus at 5 plaque-forming units/cell. At 3 days post-infection, the culture medium was recovered. After centrifugation, it was analyzed by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the gel was stained with silver. In a typical infection, 250 ml of medium were collected from 5–6x10⁶ cells.

**Chondrocyte Culture**

Cell culture was performed according to procedures described previously (19).

**Ch21 Protein Purification**

The Ch21 protein was pured from the spent culture medium of hypertrophic chondrocytes and from the culture medium of baculovirus-infected cells by the same procedure. Aliquots of media from baculovirus-infected cells were combined 10 times with a Centricon 10 to a volume of 5 ml, dialyzed against 30 mm Tris-HCl, pH 7.4, 0.3 M NaCl, and loaded on a 2.5 x 35 cm ACA54 column equilibrated with the same buffer. The column was developed at 20 ml/h, and fractions of 2 ml were collected. The culture media from baculovirus-infected cells yielded a substantially pure preparation of Ch21 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (44). Media from cultured chondrocytes were concentrated 100 times by ammonium sulfate precipitation, followed by Centriprep 10 filtration. The Ch21 purified from chondrocyte culture medium required an additional purification step on a Mono Q column (see next paragraphs).

**Separation of Ch21 Isoforms**

In the medium from both baculovirus-infected cells and chondrocytes, the Ch21 protein is present in two isoforms (~50% each) that differ in the presence of two additional alamines at the amino terminus (40). Separation of the two isoforms was achieved by HPLC gradient chromatography on a Mono Q column from Pharmacia: buffer A (20 mm phosphate buffer, pH 8); buffer B (20 mm phosphate buffer, pH 8, 0.25 M NaCl); gradient, 100% B in 60 min; flow rate, 0.5 ml/min.

**Polyacrylamide Gel Electrophoresis**

Electrophoresis of Ch21 Protein in Native Conditions—Electrophoresis was performed essentially as described (41). The lower gel was 10% acrylamide in 0.37 M Tris-HCl, pH 9.2. The upper gel was 4.5% acrylamide in 44 mm Tris phosphate, pH 6. The upper chamber running buffer was 46 mm Tris glycine, pH 8.4. The lower chamber running buffer was 63 mm Tris-HCl, pH 7.4.

Ch21 protein was incubated in phosphate-buffered saline at different concentrations of fatty acids at 4 °C overnight. Fatty acids were dissolved in ethanol and added to the reaction mixture in a volume that did not exceed 1% of ethanol. After the incubation, 20% glycerol and 0.005% bromophenol blue were added and the sample was loaded onto the gel. Electrophoresis was performed at 20 mA at 4 °C.

When indicated, extraction of the endogenous ligand was performed before electrophoresis. The protein was acidified to pH 4 with acetic acid and extracted twice with 12 volumes of ethyl acetate for 45 min at 4 °C. The remaining ethyl acetate was removed from the aqueous phase by evaporation during a brief centrifugation under vacuum.

After electrophoresis, the proteins were detected by silver staining. When proteins preincubated with radioactive fatty acids were analyzed, an aliquot of nonradioactive control protein was run in parallel. After electrophoresis, the gel was divided into two parts. The half with the non-radioactive control protein was detected by silver stain, and the half with the radioactive sample was exposed for autoradiography.

**Polyacrylamide Gel Electrophoresis of Proteins in Sodium Dodecyl Sulfate Denaturing Conditions—Standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed according to published procedures both in reducing and nonreducing conditions (42). Gel concentration was 15%.

**Radiolabeled Fatty Acid Binding Assay**

Binding assay was performed essentially as described (43). Hydroxylalkoxypropyl dextran type III from Sigma (equivalent to Lipidex 1000 from Packard Instruments) was utilized. Before the assay, the resin was swollen in ethanol and extensively washed with PBS by filtration/centrifugation in a small column. The Ch21 protein solution was incubated with the radioactive ligand (dissolved in ethanol; final concentration of ethanol 1% or less) overnight at 4 °C in 250 μl of PBS in siliconized Eppendorf tubes. After incubation, 10 mg of the equilibrated lipophilic resin were added, the mixture was shaken and the incubation was continued for 10 min at 0 °C. After centrifugation in an Eppendorf centrifuge for 3 min at 4 °C, 200 μl of supernatant were carefully withdrawn and counted for radioactivity.

**Western Blotting**

After polyacrylamide gel electrophoresis, the gel was blotted to a BAB5 nitrocellulose membrane (Schleicher & Schuell GmbH, Dassel, Germany) according to the procedure described by Towbin et al. (44). The blot was saturated for 16 h with 5% nonfat cow milk in TTBS buffer (20 mm Tris-HCl, pH 7.5, 500 mm NaCl, 0.05% Tween 20), washed several times with TTBS and incubated with purified anti Ch21 antibodies in 5% low fat milk in TTBS for 3 h at room temperature. After washing with TTBS, the protein was detected with an alkaline phosphatase-conjugated anti-rabbit IgG (Boehringer Mannheim GmbH, Mannheim, Germany) (1:2,000 in 5% low fat milk in TTBS). After additional washing with TTBS, the blot was washed in a solution of 20 mm NaCl, 5 mm MgCl₂, 100 mm Tris-HCl, pH 9.5. Finally the blot was exposed to the substrate solution (Western Blue Stabilized substrate for alkaline phosphatase, Promega, Madison, WI). The reaction was quenched with 20 mm Tris-HCl, 20 mm EDTA, pH 7.2.

**RESULTS**

Expression of Recombinant Ch21 by Baculovirus-infected Cells

An electrophoretic pattern of proteins released by control and Ch21 recombinant baculovirus-infected Sf9 cells is presented in Fig. 1. A band that was absent in the supernatant of Sf9 cells, infected both with the wild type and a control unrelated recombinant virus, was present in the culture medium of cells infected with the Ch21 recombinant virus. This band had the same electrophoretic mobility of labeled Ch21 from chicken.
The Ch21 protein was purified from baculovirus-infected cell medium by gel filtration on ACA 54 column (Fig. 2). The Ch21 recovered from the symmetrical peak in the protein profile appeared substantially pure by polyacrylamide gel electrophoresis both under reducing and non-reducing conditions (Fig. 2, inset). In a typical purification, 2–5 mg of Ch21 were obtained from 1 liter of medium.

We have reported the existence in chondrocyte culture medium of two isoforms present in about 50% ratio and differing for the presence of two extra residues of alanine at the amino terminus of one form (40). The two isoforms were also separated by anion exchange chromatography from the purified recombinant protein (Fig. 3). Mass spectra of the two isoforms were acquired using a Hewlett Packard 5989A single quadrupole mass spectrometer equipped with an electrospray ionization source. The obtained mass of the two isoforms (respectively 18,051 and 17,909) was in agreement with the molecular weight calculated from the amino acid sequence of the isoforms purified from chondrocyte medium. Therefore, an identical proteolytic processing of the Ch21 occurs in avian and insect cells.

Identification of the Ch21 Ligand

Binding of Fatty Acids to the Protein—The purified recombinant Ch21 was analyzed by gel electrophoresis under native conditions following the protocol used to analyze the retinol-binding protein (41). Two forms of the protein, presenting different electrophoretic mobilities due to different electric charges, were separated (Fig. 4). Treatment of the protein with ethyl acetate in acid conditions (pH 4) prior to electrophoresis, proteins were detected by silver stain (lanes 1–3) or by autoradiography (lane 4). The purified recombinant virus; lane 2, control uninfected cells; lane 3, cells infected with the Ch21 recombinant virus; lane 4, labeled proteins released by radioactively labeled cultured chicken hypertrophic chondrocytes. After electrophoresis, proteins were detected by silver stain (lanes 1–3) or by autoradiography (lane 4).

In the attempt to identify the ligand, the purified recombinant protein was incubated with different hydrophobic ligands at different concentrations: retinol, retinoic acid, steroids and fatty acids. We observed a shift in the electrophoretic mobility only with fatty acids (linoleic, oleic, and stearic acid) at concentrations of $10^{-5}$ M (Fig. 4B). The band of the less anodic form was almost completely replaced by a band comigrating with the more anodic form of the purified protein.

Next we incubated the protein with radiolabeled linoleic acid in the absence and in the presence of a 100-fold excess of non-radioactive linoleic acid. After electrophoresis of the incubated samples, the polyacrylamide gel was divided and either stained with silver or dried and exposed for autoradiography. The radioactive ligand binds only to the more anodic form of the protein and is displaced by the non-radioactive ligand excess (Fig. 4C).

To investigate whether both isoforms, differing only in alanine residues, were capable of binding fatty acids, we performed experiments with the two isoforms separated by Mono Q column chromatography. After chromatography, both isoforms loose endogenous ligand, although a small amount of ligand-protein complex was still detectable in several protein preparations. Treatment of both isoforms with $10^{-5}$ M linoleic or oleic acid resulted in the reappearance or in a dramatic increase of the more anodic form (not shown).
linoleic acid.

several radioactive fatty acids at 1
conditions for Ch21-fatty acid binding. Based on these results,
complex.
and the fatty acid, and [Ch21-FA] is the concentration of the
in the presence (lane 2) and in the absence (lane 3) of 100-fold excess of non-radioactive
Dissociation Constant Determination of the Fatty Acid-Ch21 Complex—In preliminary experiments, we determined limiting conditions for Ch21-fatty acid binding. Based on these results, several radioactive fatty acids at 1 × 10^{-7} M were incubated with the recombinant purified Ch21 at concentrations ranging from 1 × 10^{-8} to 2 × 10^{-6} M. Concentrations of Ch21 protein were determined based on amino acid analysis performed in triplicate. Both isoforms of the protein were analyzed in independent assays with identical results. To avoid duplication, only results obtained with one isoform are presented. The binding curves of the protein with linoleic, oleic, arachidonic, stearic, and myristic acid are presented in Fig. 5. Unsaturated fatty acids bind with a $K_a$ in the order of 2 × 10^{-7} M, while stearic acid binds with a $K_a$ of 5 × 10^{-7} M and myristic acid with a $K_a$ of 1 × 10^{-6} M. Calculation of the equilibrium binding constants was performed with the following equilibrium equation from the midpoints of the curves (45).

$$[\text{Ch21-FA}] = \frac{[\text{Ch21}]_0 \times [\text{FA}]_0 - [\text{Ch21-FA}]_0}{1 + [\text{FA}]_0 - [\text{Ch21-FA}]_0}$$

(\text{Eq. 1})

[Ch21]_0 and [FA]_0 are the total concentrations of the protein and the fatty acid, and [Ch21-FA] is the concentration of the complex. $K_a$ is the association constant; $K_d$ is 1/$K_a$.

The fatty acid binding to the protein appears specific. Displacement of the radioactive fatty acid by high concentrations of the non-radioactive ligand was complete (data not shown). Other hydrophobic small molecules, such as retinoic acid and progesterone, did not bind to the protein when tested at the same concentration range.

When the binding of fatty acid of different chain lengths, saturated and unsaturated, was tested by a competition assay with labeled oleic acid, we observed that short-chain fatty acid did not displace the binding of oleic acid to Ch21 protein and that medium-chain unsaturated fatty acid displaced the binding better than the saturated fatty acid of the same length (Table I). Interestingly, long-chain aldehyde and alcohol did not displace the oleic acid binding.

Since arachidonic acid was bound with high affinity, we investigated the possible binding of some of its metabolites, namely prostaglandins (Table I). The radioactive arachidonic acid bound to the protein was displaced, as expected, by non-radioactive arachidonic acid. In contrast, the radioactive arachidonic acid was not displaced by prostaglandin D₂ or prosta-

 glandin E₂.

Molecular Weight of the Fatty Acid-Ch21 Complex—The data of Table I indicate that saturation of binding was obtained with a ligand/protein molar ratio of 0.66:1. Saturation of binding at the same molar ratio was observed when progressively increasing concentrations of arachidonic acid were added to a fixed concentration of protein (Fig. 6). Among the possible explanations for a binding saturation at a molar ratio lower than 1 could be the presence of an inactive fraction of protein, binding of some endogenous ligand or a requirement for a protein dimer for generation of a ligand binding site. To distinguish among these possibilities, we determined the molecular weight of the protein previously incubated with linoleic acid at a saturating concentration (1:1 molar ratio) (Fig. 7). The elution volume of the recombinant Ch21 after chromatography on a Superdex 75 column before and after incubation with the linoleic acid remained the same. In both cases the calculated molecular weight was 18,000, in agreement with the molecular weight determined from the amino acid composition, mass spectrometry, and the sodium dodecyl sulfate-polyacrylamide gel elec-
Extracellular Fatty Acid-binding Protein

Within the context of the lipocalin family (23), the Ch21 protein is a low molecular weight protein that is expressed by hypertrophic chondrocytes. We have shown previously that the Ch21 is expressed also by cell types other than cartilage and bone cells, including granulocytes (22). We therefore investigated by Western blot for the presence of the protein in the chicken serum (Fig. 8). The specific antibodies recognized in the serum a protein with the same electrophoretic mobility of the purified recombinant Ch21 and of the Ch21 present in the conditioned medium of hypertrophic chondrocytes. No cross-reacting protein was observed in control bovine serum.

**DISCUSSION**

In this study we have demonstrated that Ch21, a low molecular weight protein of the lipocalin family expressed by hypertrophic chondrocytes in vitro and in vivo (19–22), binds fatty acids, that the binding is saturable, and that the protein binds ligands as a monomer with a molecular weight of the order of 10^4. Long-chain unsaturated fatty acids are preferential ligands. Short-chain fatty acids and long-chain aldehyde and alcohol do not displace the bound long-chain fatty acids. These findings raise the question of the importance of fatty acids in cartilage development and bone formation.

The cascade of events leading to endochondral bone formation from an entirely cartilaginous tissue is not completely understood. The finding that the binding of fatty acids to Ch21 is saturable and that the protein binds fatty acids as a monomer with a molecular weight of the order of 10^4 suggests that this protein might be involved in the regulation of the intracellular fatty acid concentration in hypertrophic chondrocytes.

**Fig. 6.** Representative saturation experiment. A fixed limiting amount of radioactive recombinant purified Ch21 (2.4 × 10^-7 M) was incubated with increasing concentrations of arachidonic acid (μM). Each point was assayed in duplicate and repeated twice.

**Fig. 7.** Molecular weight determination of the fatty acid-Ch21 complex on Superdex 75 HPLC column. After incubation with radioactive linoleic acid the isoform A of the recombinant Ch21 was analyzed as described under “Experimental Procedures.” BSA, bovine serum albumin; SBTI, soybean trypsin inhibitor. Inset shows analysis of sample by native gel electrophoresis. Lane 1, control Ch21, silver-stained. Lane 2, protein in the chromatographic peak, autoradiography.
Extracellular Fatty Acid-binding Protein

known, although some information is available. Hypertrophic chondrocytes play an active role in bone formation both for the deposition of the first bone (10–14) and because they synthesize and secrete diffusible factors promoting angiogenesis, and possibly stimulating growth and differentiation of surrounding osteoblasts and preosteoblasts (16–18).

The presence of lipids has been shown in cartilage, in particular in cytoplasmic dense bodies of epiphyseal chondrocytes, in the pericellular space, and in calcifying matrix (47), but the role of these lipids and their significance remain unclear. The presence of free fatty acids released by the action of phospholipase A₂ from plasmamembrane phospholipids of growth plate chondrocytes has also been described (48). Vitamin D derivatives modulate phospholipase A₂ activity in cartilage. Phospholipase A₂ activity is required for fatty acid turnover and is the rate-limiting step in production of prostaglandins and other arachidonic acid derived metabolites. A molecule derived from arachidonic acid following the action of lipoxigenase, the 5,12S-diHETE, has been identified in osteoblasts and epiphyseal chondrocytes (49). Although in articular chondrocytes synthesis and response to prostaglandins, molecules derived from arachidonic acid following the action of cyclooxygenase, have been reported by several authors, little information is available on prostaglandins in growth plate chondrocytes. Indirect evidence for the presence of prostaglandins in calcified cartilage has been obtained by Okiji et al. (50), who have demonstrated by immunohistochemistry expression of prostaglandin-1₂-synthase by chondrocytes in demineralized sections of rat tissues.

Prostaglandin E₁ induces angiogenesis in an in vivo assay (51). It is interesting to note that Harada et al. (52) have reported potent stimulation of bone formation in cell cultures following increased expression of the angiogenic factor VEGF induced by prostaglandin E₁ and E₂.

It is tempting to speculate that Ch21 has a function in the transport of free fatty acids released from membrane phospholipids or storage lipids. Due to their hydrophobicity, fatty acids cannot diffuse freely in the hydrophilic extracellular microenvironment. Therefore, the requirement for a carrier protein capable of forming a soluble complex with these molecules and of presenting them to cells may be important to the synthesis of active fatty acid metabolites by the cells. Intraacellular fatty acid-binding proteins have been described (32–37), but to our knowledge the Ch21 is the first extracellular protein selectively binding fatty acids described in peripheral tissues. The enrichment of Ch21 in tissues differentiating and/or undergoing morphogenesis could be explained by the increased local require-

REFERENCES

1. Kosher, R. A. (1983) in Cartilage (Hall, B. K., ed) Vol. 1, pp. 59–85, Academic Press, New York

2. Owen, M. (1985) Bone Miner. Res. 3, 1–25

3. Capasso, O., Giorni, E., Pontarelli, G., Ambesi-Imp佐bato, F. S., Nitsch, L., Tajana, G., and Cancello, R. (1982) Exp. Cell Res. 142, 197–206

4. Schmid, T. M., and Linsenmayer, T. F. (1983) J. Biol. Chem. 258, 5968–5975

5. Capasso, O., Tajana, G., and Cancello, R. (1984) Mol. Cell. Biol. 4, 1163–1168

6. Schmid, T. M., and Linsenmayer, T. F. (1985) Dev. Biol. 107, 373–381

7. Hayashi, M., Ninomiya, Y., Parsons, J., Hayashi, K., Olsen, B. R., and Ronchi, S. (1990) J. Cell Biol. 110, 2301–2309

8. Castagnola, P., Diöz, B., Moro, G., and Cancello, R. (1988) J. Biol. Chem. 263, 461–467

9. Descalzi Cancello, F., Gentili, C., Manduca, P., and Cancello, R. (1992) J. Cell Biol. 117, 427–435

10. Strauss, P. G., Closs, E. I., Schmidt, J., and Erffe, V. (1990) J. Cell Biol. 110, 1369–1378

11. Yoshida, K., and Yagi, T. (1989) J. Craniofacial Genet. Dev. Biol. 8, 253–264

12. Roach, H. I., and Shearer, J. R. (1989) Bone Miner. 6, 289–309

13. Galotto, M., Campanile, G., Robino, G., Descalzi Cancello, F., Bianco, P., and Cancedda, R. (1994) J. Biol. Chem. 269, 23145–23148

14. Galotto, M., Campanile, G., Banfi, A., Trugli, M., and Cancello, R. (1985) Eur. J. Cell Biol. 67, 99–105

15. Levi, G., Pitar, T., Schneider-Maunoury, S., Lasagna, M., Mantero, S., Cancello, R., and Charnay, P. (1996) Development 122, 113–120

16. Descalzi Cancello, F., Melchiori, A., Benelli, R., Gentili, C., Masielio, L., Campanile, G., Cancello, R., and Albin, A. (1995) Eur. J. Cell Biol. 66, 62–68

17. Gentili, C., Bianco, P., Neri, M., Malpeli, G., Campanile, G., Castagnola, P., Cancello, R., and Descalzi Cancello, F. (1993) J. Cell Biol. 122, 703–712

18. Gentili, C., Doliana, R., Bet, R., Campanile, G., Cembali, A., Descalzi Cancello, F., and Cancello, R. (1994) J. Cell Biol. 124, 579–588

19. Descalzi Cancello, F., Manduca, P., Tachetti, C., Fossa, P., Quarto, R., and Cancello, R. (1989) J. Cell Biol. 107, 2455–2462

20. Manduca, P., Descalzi Cancello, F., Tachetti, C., Quarto, R., and Cancello, R. (1989) Eur. J. Cell Biol. 50, 154–161

21. Descalzi Cancello, F., Dozin, B., Rossa, F., Molina, F., Cancello, R., Negri, A., and Ronchi, S. (1990) J. Cell Biol. 107, 253–264

22. Dozin, B., Descalzi, F., Briata, L., Hayashi, M., Gentili, C., Hayashi, K., Quarto, R., and Cancello, R. (1992) J. Cell Biol. 116, 2797–2805

23. Godovac-Zimmermann, J., (1988) Trends Biochem. Sci. 13, 64–66

24. Newcomer, M. E., Jones, T. A., Aquist, J., Sundelin, J., Ekstrand, B., Rask, Q. L., and Peterson, P. A. (1984) EMBO J. 3, 1451–1454

25. Berman, P., Gray, P., Shen, E., Keyser, K., Ehrlich, D., Herten, K., LaCorbriere, M., Esch, R., and Schubert, D. (1987) Cell 51, 155–156

26. Newcomer, M. E. (1993) Structure 1, 7–18

27. Holden, H. M., Rypniewski, W. R., Lee, J. H., and Raymond, I. (1987) EMBO J. 6, 1565–1570

28. Huber, R., Schneider, M., Epp, O., Mayr, I., Messerschmidt, A., Pfaffrath, J., and Kayser, H. (1987) J. Mol. Biol. 195, 423–434

29. Cavaggioni, A., Sorri, R., T. T. Kien, N., Pappin, D. J., and Findlay, B. J. (1987) FEMS Lett. 212, 225–228

30. Pearlman, W. H., Gueriguian, J. L., and Sawyer, M. E. (1973) J. Biol. Chem. 248, 5736–5741

31. Bockel, Z., Groom, C. R., Flower, R., and Petersen, P. A. (1974) EMBO J. 3, 1451–1454

32. Berner, P., Gray, P., Shen, E., Keyser, K., Ehrlich, D., Herten, K., LaCorbriere, M., Esch, R., and Schubert, D. (1987) Cell 51, 155–156

33. Newcomer, M. E. (1993) Structure 1, 7–18

34. Holden, H. M., Rypniewski, W. R., Lee, J. H., and Raymond, I. (1987) EMBO J. 6, 1565–1570

35. Huber, R., Schneider, M., Epp, O., Mayr, I., Messerschmidt, A., Pfaffrath, J., and Kayser, H. (1987) J. Mol. Biol. 195, 423–434

36. Cavaggioni, A., Sorri, R., T. T. Kien, N., Pappin, D. J., and Findlay, B. J. (1987) FEMS Lett. 212, 225–228

37. Pearlman, W. H., Gueriguian, J. L., and Sawyer, M. E. (1973) J. Biol. Chem. 248, 5736–5741

38. Bockel, Z., Groom, C. R., Flower, R., and Petersen, P. A. (1974) EMBO J. 3, 1451–1454
Extracellular Fatty Acid-binding Protein

38. Douglas Ashbrook, J. D., Spector, A. A., Santos, E. C., and Fletcher, J. E. (1975) J. Biol. Chem. 250, 2333–2338
39. Summers, M. D., and Smith, G. E. (1987) Tex. Agric. Exp. Stn. Bull. 1555
40. Descalzi Cancedda, F., Asaro, D., Molina F., Cancedda, R., Caruso, C., Camardella, L., Negri, A., and Ronchi, S. (1990) Biochem. Biophys. Res. Commun. 188, 933–938
41. Rodbard, D., and Chrambach, A., (1971) Anal. Biochem. 40, 95–134
42. Laemmli, U. K., (1970) Nature 227, 680–685
43. Hubbell, T., Behnke, W. D., Woodford, J. K., and Schroeder, F. (1994) Biochemistry 33, 3327–3334
44. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350–4354
45. Corsetti, M. T., Briata, P., Sanseverino, L., Daga, A., Airoldi, I., Simeone, A., Palmisano, G., Angelini, C., Boncinelli, E., and Corte, G. (1992) Nucleic Acids Res. 20, 4465–4472
46. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., and Piomelli, D. (1994) Nature 372, 686–691
47. Borucchi, E., and Silvestrini, G. (1994) Bone 15, 153–160
48. Swain, L. D., Schwartz, Z., and Boyan, B. D. (1992) Bone Miner. 17, 192–196
49. Yang, C. Y., Meng, C. L., and Wong, P. Y. (1992) Eicosanoids 5, 109–113
50. Okiji, T., Morita, I., Kawashima, N., Kosaka, T., Suda, H., and Murota, S. (1993) Arch. Oral. Biol. 38, 31–36
51. Diaz Flores, L., Gutierrez, R., Valladares, F., Varela, H., and Perez, M. (1994) Anat. Rec. 238, 68–76
52. Harada, S., Nagy, J. A., Sullivan, K. A., Thomas, K. A., Endo, N., Rodan, G. A., and Rodan, S. B. (1994) J. Clin. Invest. 93, 2490–2496